BR9911357A - Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragility - Google Patents

Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragility

Info

Publication number
BR9911357A
BR9911357A BR9911357-0A BR9911357A BR9911357A BR 9911357 A BR9911357 A BR 9911357A BR 9911357 A BR9911357 A BR 9911357A BR 9911357 A BR9911357 A BR 9911357A
Authority
BR
Brazil
Prior art keywords
fragility
ghs
serm
modulators
selective
Prior art date
Application number
BR9911357-0A
Other languages
Portuguese (pt)
Inventor
Hua Zhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Producs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Producs Inc filed Critical Pfizer Producs Inc
Publication of BR9911357A publication Critical patent/BR9911357A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Patente de Invenção: <B>"COMBINAçõES TERAPêUTICAS DE MODULADORES (SELETIVOS) DE RECEPTOR DE ESTROGêNIO (SERM) E SECRETAGOGOS DE HORMÈNIO DE CRESCIMENTO (GHS) PARA TRATAR FRAGILIDADE MúSCULO-ESQUELETAL"<D>. Esta invenção refere-se a combinações de composições farmacêuticas e a métodos que contenham (-)-cis-6-fenil-5-(4-(2-pirrolidin-1-il-etóxi)-fenil)-5,6,7,8-tetrehidronaftale n-2-ol ou um seu sal farmaceuticamente aceitável e 2-amino-N-(1(R)-(2,4-difluoro-benziloximetil)-2-oxo-2-(3-oso-3a (R)-piridin-2-ilmetil)-2-(2,2,2-trifluoro-etil)-2,3,3a,4,6,7-hexahidro-piraz olo [4,3,-c] piridin-5-il)-etil)-2-metil-propionamida ou um seu sal farmaceuticamente aceitável, métodos para a utilização de tais composições e kits que contenham tais composições. As composições são úteis para o tratamento de fragilidade musculo-esqueletal, incluindo a osteoporose, a fratura osteoporótica, a fraca massa óssea, a fragilidade e a fraca massa muscular.Patent of Invention: <B> "THERAPEUTIC COMBINATIONS OF MODULATORS (SELECTIVE) OF ESTROGEN RECEPTOR (SERM) AND SECRETAGOGRAPHY OF GROWTH HORMONE (GHS) TO TREAT MUSCLE-SKELETAL FRAGILITY" <D>. This invention relates to combinations of pharmaceutical compositions and to methods containing (-) - cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -5,6,7 , 8-tetrehydronaftale n-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N- (1 (R) - (2,4-difluoro-benzyloxymethyl) -2-oxo-2- (3-oso-3a (R) -pyridin-2-ylmethyl) -2- (2,2,2-trifluoro-ethyl) -2,3,3a, 4,6,7-hexahydro-pyrazole [4,3, -c] pyridin -5-yl) -ethyl) -2-methyl-propionamide or a pharmaceutically acceptable salt thereof, methods for using such compositions and kits containing such compositions. The compositions are useful for the treatment of musculoskeletal fragility, including osteoporosis, osteoporotic fracture, weak bone mass, fragility and weak muscle mass.

BR9911357-0A 1998-06-16 1999-05-03 Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragility BR9911357A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16
PCT/IB1999/000796 WO1999065488A1 (en) 1998-06-16 1999-05-03 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Publications (1)

Publication Number Publication Date
BR9911357A true BR9911357A (en) 2001-03-13

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911357-0A BR9911357A (en) 1998-06-16 1999-05-03 Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragility

Country Status (29)

Country Link
EP (1) EP1085867A1 (en)
JP (1) JP2002518328A (en)
KR (1) KR20010052817A (en)
CN (1) CN1305378A (en)
AP (1) AP9901581A0 (en)
AR (1) AR018868A1 (en)
AU (1) AU3342099A (en)
BG (1) BG105128A (en)
BR (1) BR9911357A (en)
CA (1) CA2335112A1 (en)
CO (1) CO5070586A1 (en)
EA (1) EA200001189A1 (en)
GT (1) GT199900083A (en)
HR (1) HRP20000857A2 (en)
HU (1) HUP0102395A2 (en)
ID (1) ID26726A (en)
IL (1) IL139587A0 (en)
IS (1) IS5727A (en)
MA (1) MA26648A1 (en)
NO (1) NO20006381D0 (en)
OA (1) OA11569A (en)
PA (1) PA8472101A1 (en)
PE (1) PE20000633A1 (en)
PL (1) PL345064A1 (en)
SK (1) SK18902000A3 (en)
TN (1) TNSN99118A1 (en)
UY (1) UY25557A1 (en)
WO (1) WO1999065488A1 (en)
ZA (1) ZA993973B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
DK1460969T3 (en) * 2001-11-29 2008-09-01 Gtx Inc Prevention and treatment of androgen deprivation caused by osteoporosis
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
EP2118080B1 (en) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (en) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS

Also Published As

Publication number Publication date
AP9901581A0 (en) 1999-06-30
CN1305378A (en) 2001-07-25
EP1085867A1 (en) 2001-03-28
CO5070586A1 (en) 2001-08-28
HUP0102395A2 (en) 2001-11-28
AR018868A1 (en) 2001-12-12
AU3342099A (en) 2000-01-05
ID26726A (en) 2001-02-01
PE20000633A1 (en) 2000-07-26
HRP20000857A2 (en) 2001-10-31
OA11569A (en) 2004-07-01
IL139587A0 (en) 2002-02-10
UY25557A1 (en) 2001-01-31
EA200001189A1 (en) 2001-06-25
NO20006381L (en) 2000-12-14
PL345064A1 (en) 2001-11-19
CA2335112A1 (en) 1999-12-23
GT199900083A (en) 2000-12-05
PA8472101A1 (en) 2000-09-29
JP2002518328A (en) 2002-06-25
TNSN99118A1 (en) 2005-11-10
SK18902000A3 (en) 2001-12-03
KR20010052817A (en) 2001-06-25
WO1999065488A1 (en) 1999-12-23
BG105128A (en) 2001-11-30
IS5727A (en) 2000-11-24
ZA993973B (en) 2000-12-15
MA26648A1 (en) 2004-12-20
NO20006381D0 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
YU18400A (en) Prostaglandin agonists and their use to treat bone disorders
BR0309875A (en) methods and compositions for treating peripheral nervous system disorders and novel compounds useful therefor
EA200400735A1 (en) 3-β-D-RIBOFURANOSYLTIAZOLO [4,5-d] Pyrimidine Nucleoside and Their Uses
DE60037836D1 (en) ThiazoloÄ4,5-diphyrimidine compounds for the treatment of rheumatoid arthritis
WO2000021926A3 (en) 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS
EE04018B1 (en) Thieno [2,3-d] pyrimidinediones, process for their preparation and pharmaceutical compositions containing them
HUP0402270A2 (en) [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
BR0100558A (en) Compositions and methods for treating osteoporosis
NO993027D0 (en) Pyrrolo [3,4-D] pyrimidinone derivatives and their use as drugs
BR9911357A (en) Therapeutic combinations of estrogen receptor (serm) (selective) modulators and growth hormone secretagogues (ghs) to treat musculoskeletal fragility
CA2325842A1 (en) Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
BR9911228A (en) Therapeutic combinations comprising a selective modulator of an estrogen receptor and parathyroid hormone
BR9911324A (en) Therapeutic combinations of estrogen receptor (selective) modulators (serm) and growth hormone secretagogues (ghs) for the treatment of musculoskeletal fragility
BR0112619A (en) Compound, process for preparing it, pharmaceutical formulation, use of a compound, methods for treating 5-hydroxytryptamine-mediated disorders, and disorders of the central nervous system and / or overactive bladder or vasospasm or for growth control of tumors
ECSP993021A (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY
CA2274381A1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
ECSP993020A (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
TH57984A3 (en) A therapeutic combination consisting of selective estrogen receptor modulators and parathyroid hormone.
TH48282A (en) Treatment of diseases of the drug combination of osteoporosis.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]